Key Points
- CEO Pardeep Nijhawan purchased 30,000 shares of Edesa Biotech (NASDAQ:EDSA) on Feb. 27 at $2.22 per share for $66,600, raising his direct stake to 371,702 shares (an 8.78% increase in his ownership).
- He also bought 20,571 shares on Feb. 26 at $1.58 per share ($32,502.18), meaning Nijhawan acquired a total of 50,571 shares over two days for roughly $99,102.
- Company context: Edesa Biotech has a market cap of about $19.0M, a negative trailing P/E, a 1‑year price range of $0.72–$2.95, and a consensus analyst price target of $5.00 amid mixed Buy/Sell ratings (marketbeat average: Hold).
Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan acquired 20,571 shares of the business's stock in a transaction dated Thursday, February 26th. The stock was purchased at an average price of $1.58 per share, for a total transaction of $32,502.18. Following the completion of the acquisition, the chief executive officer owned 615,797 shares in the company, valued at approximately $972,959.26. This trade represents a 3.46% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Pardeep Nijhawan also recently made the following trade(s):
- On Friday, February 27th, Pardeep Nijhawan bought 30,000 shares of Edesa Biotech stock. The shares were purchased at an average price of $2.22 per share, with a total value of $66,600.00.
Edesa Biotech Stock Performance
EDSA opened at $2.28 on Tuesday. Edesa Biotech, Inc. has a 1 year low of $0.72 and a 1 year high of $2.95. The firm has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.87. The company has a market cap of $19.04 million, a PE ratio of -1.98 and a beta of 0.04.
Edesa Biotech (NASDAQ:EDSA - Get Free Report) last announced its quarterly earnings results on Friday, February 13th. The company reported ($0.28) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.28). The business had revenue of $0.10 million for the quarter. On average, sell-side analysts predict that Edesa Biotech, Inc. will post -1.75 earnings per share for the current year.
Institutional Investors Weigh In On Edesa Biotech
Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp acquired a new stake in shares of Edesa Biotech during the 4th quarter valued at about $27,000. Susquehanna International Group LLP bought a new position in Edesa Biotech during the third quarter valued at approximately $36,000. Diadema Partners LP acquired a new stake in Edesa Biotech in the fourth quarter valued at approximately $77,000. Finally, DRW Securities LLC bought a new stake in Edesa Biotech in the fourth quarter worth approximately $191,000. 5.50% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research firms have commented on EDSA. Weiss Ratings reissued a "sell (e+)" rating on shares of Edesa Biotech in a research report on Monday, December 29th. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Edesa Biotech in a report on Monday, November 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $5.00.
Get Our Latest Stock Analysis on Edesa Biotech
Edesa Biotech Company Profile
(
Get Free Report)
Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa's approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.
Among Edesa's pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
